Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines.

Geuns-Meyer S, Cee VJ, Deak HL, Du B, Hodous BL, Nguyen HN, Olivieri PR, Schenkel LB, Vaida KR, Andrews P, Bak A, Be X, Beltran PJ, Bush TL, Chaves MK, Chung G, Dai Y, Eden P, Hanestad K, Huang L, Lin MH, Tang J, Ziegler B, Radinsky R, Kendall R, Patel VF, Payton M.

J Med Chem. 2015 Jul 9;58(13):5189-207. doi: 10.1021/acs.jmedchem.5b00183. Epub 2015 May 31.

PMID:
25970324
2.

AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.

Juan G, Bush TL, Ma C, Manoukian R, Chung G, Hawkins JM, Zoog S, Kendall R, Radinsky R, Loberg R, Friberg G, Payton M.

J Transl Med. 2014 Nov 4;12:307. doi: 10.1186/s12967-014-0307-x.

3.

Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity.

Graves JD, Kordich JJ, Huang TH, Piasecki J, Bush TL, Sullivan T, Foltz IN, Chang W, Douangpanya H, Dang T, O'Neill JW, Mallari R, Zhao X, Branstetter DG, Rossi JM, Long AM, Huang X, Holland PM.

Cancer Cell. 2014 Aug 11;26(2):177-89. doi: 10.1016/j.ccr.2014.04.028. Epub 2014 Jul 17.

4.

AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.

Bush TL, Payton M, Heller S, Chung G, Hanestad K, Rottman JB, Loberg R, Friberg G, Kendall RL, Saffran D, Radinsky R.

Mol Cancer Ther. 2013 Nov;12(11):2356-66. doi: 10.1158/1535-7163.MCT-12-1178. Epub 2013 Aug 29.

5.

Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.

Peterson EA, Boezio AA, Andrews PS, Boezio CM, Bush TL, Cheng AC, Choquette D, Coats JR, Colletti AE, Copeland KW, DuPont M, Graceffa R, Grubinska B, Kim JL, Lewis RT, Liu J, Mullady EL, Potashman MH, Romero K, Shaffer PL, Stanton MK, Stellwagen JC, Teffera Y, Yi S, Cai T, La DS.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):4967-74. doi: 10.1016/j.bmcl.2012.06.033. Epub 2012 Jun 16.

PMID:
22765895
6.

Discovery of triazine-benzimidazoles as selective inhibitors of mTOR.

Peterson EA, Andrews PS, Be X, Boezio AA, Bush TL, Cheng AC, Coats JR, Colletti AE, Copeland KW, DuPont M, Graceffa R, Grubinska B, Harmange JC, Kim JL, Mullady EL, Olivieri P, Schenkel LB, Stanton MK, Teffera Y, Whittington DA, Cai T, La DS.

Bioorg Med Chem Lett. 2011 Apr 1;21(7):2064-70. doi: 10.1016/j.bmcl.2011.02.007. Epub 2011 Feb 12.

PMID:
21376583
7.

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.

Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, Ross S, Cee VJ, Deak HL, Hodous BL, Nguyen HN, Olivieri PR, Romero K, Schenkel LB, Bak A, Stanton M, Dussault I, Patel VF, Geuns-Meyer S, Radinsky R, Kendall RL.

Cancer Res. 2010 Dec 1;70(23):9846-54. doi: 10.1158/0008-5472.CAN-10-3001. Epub 2010 Oct 8.

8.

Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.

Cee VJ, Schenkel LB, Hodous BL, Deak HL, Nguyen HN, Olivieri PR, Romero K, Bak A, Be X, Bellon S, Bush TL, Cheng AC, Chung G, Coats S, Eden PM, Hanestad K, Gallant PL, Gu Y, Huang X, Kendall RL, Lin MH, Morrison MJ, Patel VF, Radinsky R, Rose PE, Ross S, Sun JR, Tang J, Zhao H, Payton M, Geuns-Meyer SD.

J Med Chem. 2010 Sep 9;53(17):6368-77. doi: 10.1021/jm100394y.

PMID:
20684549
9.

Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.

Caenepeel S, Renshaw-Gegg L, Baher A, Bush TL, Baron W, Juan T, Manoukian R, Tasker AS, Polverino A, Hughes PE.

J Exp Clin Cancer Res. 2010 Jul 15;29:96. doi: 10.1186/1756-9966-29-96.

10.

The Washington County Training Center: an exemplar of public health research in the field.

Comstock GW, Bush TL, Helzlsouer KJ, Hoffman SC.

Am J Epidemiol. 2008 Oct 1;168(7):676-82. doi: 10.1093/aje/kwn270. No abstract available.

PMID:
18820266
11.

Discovery and evaluation of dual CDK1 and CDK2 inhibitors.

Payton M, Chung G, Yakowec P, Wong A, Powers D, Xiong L, Zhang N, Leal J, Bush TL, Santora V, Askew B, Tasker A, Radinsky R, Kendall R, Coats S.

Cancer Res. 2006 Apr 15;66(8):4299-308.

12.

Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women.

Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE Jr, Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Key TJ, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB, Miller SR, Longcope C; Endogenous Hormones Breast Cancer Collaborative Group.

J Natl Cancer Inst. 2003 Aug 20;95(16):1218-26.

PMID:
12928347
13.

Can obesity explain the racial difference in stage of breast cancer at diagnosis between black and white women?

Cui Y, Whiteman MK, Langenberg P, Sexton M, Tkaczuk KH, Flaws JA, Bush TL.

J Womens Health Gend Based Med. 2002 Jul-Aug;11(6):527-36.

PMID:
12225626
14.

Body mass and stage of breast cancer at diagnosis.

Cui Y, Whiteman MK, Flaws JA, Langenberg P, Tkaczuk KH, Bush TL.

Int J Cancer. 2002 Mar 10;98(2):279-83.

15.

Media coverage of women's health issues: is there a bias in the reporting of an association between hormone replacement therapy and breast cancer?

Whiteman MK, Cui Y, Flaws JA, Langenberg P, Bush TL.

J Womens Health Gend Based Med. 2001 Jul-Aug;10(6):571-7.

PMID:
11559454
16.

Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation.

Liu Y, Ding J, Bush TL, Longenecker JC, Nieto FJ, Golden SH, Szklo M.

Am J Epidemiol. 2001 Sep 15;154(6):489-94. Review.

PMID:
11549553
17.

Hormone replacement therapy and breast cancer: a qualitative review.

Bush TL, Whiteman M, Flaws JA.

Obstet Gynecol. 2001 Sep;98(3):498-508. Review.

PMID:
11530137
18.

Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality.

Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL.

Arch Intern Med. 2001 Jun 11;161(11):1413-9.

PMID:
11386890
19.

SERMs and cardiovascular disease in women. How do these agents affect risk?

Bush TL, Blumenthal R, Lobo R, Clarkson TB.

Postgrad Med. 2001 Mar;Spec No:17-24. Review.

PMID:
11296735
20.

Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: a community based study.

Althuis MD, Sexton M, Langenberg P, Bush TL, Tkaczuk K, Magaziner J, Khoo L.

Cancer. 2000 Aug 15;89(4):800-10.

PMID:
10951343
21.

Racial differences in breast cancer mortality.

Flaws JA, Bush TL, Newschaffer CJ.

Arch Fam Med. 2000 May;9(5):412-3. No abstract available.

PMID:
10810944
22.

Preserving cardiovascular benefits of hormone replacement therapy.

Bush TL.

J Reprod Med. 2000 Mar;45(3 Suppl):259-73. Review.

PMID:
10756507
23.

Low fibrinogen level: A predisposing factor for venous thromboembolic events with hormone replacement therapy.

Whiteman MK, Cui Y, Flaws JA, Espeland M, Bush TL.

Am J Hematol. 1999 Aug;61(4):271-3.

24.

Hormone replacement therapy and risk of breast cancer.

Bush TL, Whiteman MK.

JAMA. 1999 Jun 9;281(22):2140-1. No abstract available.

PMID:
10367826
25.

SERMs: the benefits of estrogen without the risks?

Cole RC, Flaws JA, Bush TL.

J Womens Health. 1998 Dec;7(10):1187-9. No abstract available.

PMID:
9929850
26.

Predictors of menopausal hot flashes.

Staropoli CA, Flaws JA, Bush TL, Moulton AW.

J Womens Health. 1998 Nov;7(9):1149-55.

PMID:
9861592
27.

Breast cancer mortality in black and in white women: a historical perspective by menopausal status.

Flaws JA, Newschaffer CJ, Bush TL.

J Womens Health. 1998 Oct;7(8):1007-15.

PMID:
9812297
28.

Lessons from HERS: the null and beyond.

Bush TL.

J Womens Health. 1998 Sep;7(7):781-3. No abstract available.

PMID:
9785302
29.

Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions.

Espeland MA, Hogan PE, Fineberg SE, Howard G, Schrott H, Waclawiw MA, Bush TL.

Diabetes Care. 1998 Oct;21(10):1589-95.

PMID:
9773716
30.

Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients.

Newschaffer CJ, Bush TL, Penberthy LE, Bellantoni M, Helzlsour K, Diener-West M.

J Gerontol A Biol Sci Med Sci. 1998 Sep;53(5):M372-8.

PMID:
9754143
31.
32.

Effects of raloxifene in postmenopausal women.

Cole RC, Flaws JA, Bush TL.

N Engl J Med. 1998 Apr 30;338(18):1313; author reply 1313-4. No abstract available.

PMID:
9565492
33.

Agreement in assessing endometrial pathology: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.

Legault C, Espeland MA, Wasilauskas CH, Bush TL, Trabal J, Judd HL, Johnson SR, Greendale GA.

J Womens Health. 1998 May;7(4):435-42.

PMID:
9611701
34.

Clomiphene analogs with activity in vitro and in vivo against human breast cancer cells.

Baumann RJ, Bush TL, Cross-Doersen DE, Cashman EA, Wright PS, Zwolshen JH, Davis GF, Matthews DP, Bender DM, Bitonti AJ.

Biochem Pharmacol. 1998 Mar 15;55(6):841-51.

PMID:
9586957
35.

Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions.

Espeland MA, Marcovina SM, Miller V, Wood PD, Wasilauskas C, Sherwin R, Schrott H, Bush TL.

Circulation. 1998 Mar 17;97(10):979-86.

PMID:
9529266
36.

Women's perception of risk of coronary artery disease.

Bush TL.

J Womens Health. 1997 Aug;6(4):477-9. No abstract available.

PMID:
9279836
37.

Comorbidity measurement in elderly female breast cancer patients with administrative and medical records data.

Newschaffer CJ, Bush TL, Penberthy LT.

J Clin Epidemiol. 1997 Jun;50(6):725-33.

PMID:
9250271
38.

Decreased vascular endothelial growth factor expression associated with tumor regression induced by (E)-2'-deoxy-2'-(fluoromethylene)cytidine (MDL 101,731).

Woessner RD, Loudy DE, Wallace CD, Montgomery LR, Cross-Doersen DE, Bush TL, Lewis MT, Prakash N, Bitonti AJ, Wright PS.

Oncol Res. 1997;9(10):543-52.

PMID:
9507532
39.

Therapeutic controversy: Estrogen replacement in menopause.

Lindsay R, Bush TL, Grady D, Speroff L, Lobo RA.

J Clin Endocrinol Metab. 1996 Nov;81(11):3829-38. No abstract available.

PMID:
8923821
40.

Antitumor and chemopreventive effects of a clomiphene analog, MDL 103,323, in mammary carcinoma.

Bitonti AJ, Baumann RJ, Bush TL, Cashman EA, Wright CL, Prakash NJ.

Anticancer Res. 1996 Sep-Oct;16(5A):2553-7.

PMID:
8917350
42.

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 4. Efficacy of risk factor management.

Forrester JS, Merz CN, Bush TL, Cohn JN, Hunninghake DB, Parthasarathy S, Superko HR.

J Am Coll Cardiol. 1996 Apr;27(5):991-1006. Review. No abstract available.

43.

In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor.

Piepmeier JM, Rabidou N, Schold SC Jr, Bitonti AJ, Prakash NJ, Bush TL.

Cancer Res. 1996 Jan 15;56(2):359-61.

44.

Serum gonadotropins and steroid hormones and the development of ovarian cancer.

Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, Comstock GW.

JAMA. 1995 Dec 27;274(24):1926-30.

PMID:
8568986
45.

Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta- carotene, lycopene, alpha-tocopherol, and selenium.

Breslow RA, Alberg AJ, Helzlsouer KJ, Bush TL, Norkus EP, Morris JS, Spate VE, Comstock GW.

Cancer Epidemiol Biomarkers Prev. 1995 Dec;4(8):837-42.

46.

Distribution and correlates of plasma fibrinogen in middle-aged women. Initial findings of the Postmenopausal Estrogen/Progestin Interventions (PEPI) study.

Stefanick ML, Legault C, Tracy RP, Howard G, Kessler CM, Lucas DL, Bush TL.

Arterioscler Thromb Vasc Biol. 1995 Dec;15(12):2085-93.

PMID:
7489228
47.

Breast cancer and hormone-replacement therapy.

Blackman JA, Bush TL.

N Engl J Med. 1995 Nov 16;333(20):1355-6; author reply 1357-8. No abstract available.

PMID:
7566034
48.

Rationale, design, and conduct of the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions.

Espeland MA, Bush TL, Mebane-Sims I, Stefanick ML, Johnson S, Sherwin R, Waclawiw M.

Control Clin Trials. 1995 Aug;16(4 Suppl):3S-19S.

PMID:
7587218
49.

The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Introduction.

Bush TL, Espeland MA, Mebane-Sims I.

Control Clin Trials. 1995 Aug;16(4 Suppl):1S-2S. No abstract available.

PMID:
7587216
50.

Supplemental Content

Support Center